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changes in plasma arylsulfatase A 
level as a compensatory biomarker 
of early parkinson’s disease
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Lysosomal dysfunction has been associated with parkinson’s disease (pD). However, the activity of 
lysosomal enzymes is heterogeneously observed in pD. We investigated whether arylsulfatase A (ARSA) 
level can be used as a fluid biomarker of PD and can reflect disease progression. Plasma ARSA level 
was measured in 55 patients with early and drug-naïve PD, 13 patients with late PD, and 14 healthy 
controls. We compared the plasma ARSA level among the groups and assessed its correlation to clinical 
parameters and striatal dopamine transporter (DAt) activity. plasma ARSA level was not correlated 
with age. the early pD group had higher plasma ARSA level than the control and late pD groups. in a 
generalized additive model including all patients with pD, the plasma ARSA level showed an inverted 
U-shape according to disease duration, peaking at 2.19 years. In patients with early PD, plasma ARSA 
level was positively correlated to parkinsonian motor score and negatively to striatal DAt activity. in 
summary, plasma ARSA level was elevated in early stage of pD, and elevated plasma ARSA level was 
correlated to the clinical and imaging markers of nigrostriatal degeneration. these results suggest that 
ARSA level is a potential biomarker of compensation in early pD.
In about 5–10% of patients, Parkinson’s disease (PD) is caused by rare, inherited forms of genetic mutations1, 
and a genome-wide association study has identified 24 loci that are linked to an altered risk of developing PD2. 
Representatively, GBA gene, the causative gene for Gaucher’s disease, which is the most common lysosomal stor-
age disease3, also constitutes the single largest risk factor of idiopathic PD4,5. Considering that many genes known 
as risk factors for PD are relevant for intracellular transport pathway to lysosomes or lysosomal function6, defects 
in this system and consequent accumulation of aggregated protein play a primary role in the pathogenesis of PD. 
Accordingly, studies have identified the fluid biomarker of lysosomal enzymes to measure the central pathological 
process in PD7–9. In particular, patients with PD have reduced level of glucocerebrosidase in the blood and cere-
brospinal fluid (CSF), which provides a value in diagnosing PD7,10.
Arylsulfatase A (ARSA) is a lysosomal acid hydrolase, whose deficiency causes metachromatic leukodystro-
phy, an autosomal recessive lysosomal storage disease11. A recent study has revealed that ARSA gene mutations 
acted as a genetic modifier, either pathogenic or protective, in PD12. Specifically, ARSA gene deficiency facilitated 
α-synuclein aggregation and cell-to-cell propagation through the molecular chaperone function of ARSA. Lower 
ARSA level has also been shown to be correlated with cognitive dysfunction.
In this study, we examined the plasma ARSA level and its associations with clinical and imaging parameters of 
PD in order to elucidate whether ARSA can be used as a fluid biomarker of PD and can reflect disease progression.
Results
The baseline demographic and clinical characteristics of the patients are summarized in Table 1. The early PD 
group had younger age at the time blood sampling than the late PD group, whereas the ages of the two groups 
were comparable with the healthy controls (HC) group. The PD groups had lower total K-MMSE scores than the 
HC group, and the late PD group had lower total K-MMSE scores than the early PD group. The sex ratio and years 
of education were not different among the groups. Between the PD groups, the late PD group had longer disease 
duration and higher UPDRS motor score than the early PD group, whereas both groups developed PD at similar 
ages.
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Independent of age, sex, and total K-MMSE score, the early PD group had significantly higher estimated 
mean plasma ARSA level than the HC group (127.87 vs. 99.10, p = 0.016) and late PD group (127.87 vs. 73.62, 
p = 0.001), whereas that of the late PD group had a trend to be lower than that in the HC group (p = 0.080, 
Fig. 1A). In a generalized additive model including all patients with PD, the plasma ARSA level showed an 
inverted U-shape according to disease duration, with a peak at 2.19 years (Fig. 1B).
In the early PD group, the plasma ARSA level was positively correlated to UPDRS motor score (r = 0.280, 
Fig. 2A) and negatively correlated to striatal DAT activity (r = −0.279, Fig. 2B). Other clinical parameters, such 
as age at onset, age at sampling, years of education, and total K-MMSE score, were not correlated to plasma ARSA 
level in patients with early or late PD.
Discussion
The present study showed that the level of plasma ARSA had an inverted U-shape according to disease duration, 
with a peak at about 2 years. In the early stage of PD, the plasma ARSA level was positively correlated to UPDRS 
motor score and striatal dopamine depletion, thereby reflecting the disease severity of PD. Considering that 
ARSA deficiency has been shown to be associated with an increase in α-synuclein aggregates12, these data indi-
cated that the plasma level of ARSA, a lysosomal enzyme, is elevated in the early stage of PD, which could be a 
novel biomarker of the compensation of nigrostriatal degeneration.
Several studies have shown a heterogeneous level of lysosomal enzyme activities in fluid biomarker or brain 
tissue in patients with PD. Glucocerebrosidase activity is consistently lower in the blood13, CSF7, or brain tissue14 
in patients with PD than in normal controls, whereas the activities of serum and CSF β-galactosidase or CSF 
β-hexosaminidase are increased8,9,15. Considering that varying levels of lysosomal enzyme activity were found in 
Variables HC Early PD group Late PD group P-value
Number 14 55 13
Age at blood sampling, y 72.5 (66.1–76.3) 69.8 (62.4–75.1) 74.6 (70.7–78.9) 0.047c
Sex, male, n (%) 5 (35.7) 30 (54.5) 7 (53.8) 0.443
Education, y 12.0 (11.3–16.5) 12.0 (6.0–14.0) 9.0 (3.5–13.0) 0.081
Total K-MMSE score 28.5 (28.0–30.0) 27.0 (26.0–28.0) 22.0 (19.0–24.5) <0.001a,b,c
Age at PD onset, y 67.1 (61.3–73.6) 65.4 (60.1–70.3) 0.507
Disease duration, y 1.5 (0.6–2.2) 8.1 (7.4–11.5) <0.001
UPDRS motor score (off) 19.0 (14.0–27.0) 45.0 (33.5–52.0) <0.001
RBD, n (%) 22 (40.0) 10 (76.9) 0.016
Medication duration, y 7.5 (5.6–10.6) NA
Table 1. Demographic and clinical characteristics of patients with healthy control and Parkinson’s disease. 
Values are expressed as median (interquartile range) or number (percentage). Significant difference between 
aHC vs. early PD, bHC vs. advanced PD, cearly PD vs. advanced PD after host-hoc group comparison of 
Bonferroni procedure. Abbreviations: K-MMSE, the Korean version of the Mini-Mental State Examination; NA, 
not applicable; PD, Parkinson’s disease; RBD, rapid eye movement sleep behavior disorder; UPDRS, Unified 
Parkinson’s Disease Rating Scale.
Figure 1. (A) Group comparison of plasma ARSA levels. The post-hoc subgroup comparison was performed 
using the Bonferroni method. (B) Relationship between plasma ARSA level and disease duration. In all 
analyses, age, sex, and total K-MMSE score were used as covariates. ARSA, arylsulfatase A; AU, arbitrary unit; 
HC, healthy controls; K-MMSE, Korean version of the Mini-Mental State Examination; PD, Parkinson’s disease.
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patients with PD with a wide range of disease duration, dynamic change in the activity of each lysosomal enzyme 
as PD progresses must be investigated. In this study, we showed a different pattern of ARSA activity according 
to PD duration, indicating that plasma ARSA levels increased within the first 2 years of the disease and then 
decreased as the disease progressed. In addition, the activity of ARSA in the early stage of PD well correlated to 
the clinical and imaging parameters of degeneration in the nigrostriatal dopaminergic neuron. Accordingly, the 
higher activity of ARSA in the early stage is either a direct marker of lysosomal dysfunction or a compensation of 
autophagic clearance of aggregated α-synuclein in neurons. Considering that ARSA depletion promoted intra-
cellular accumulation and intercellular propagation of α-synuclein and that lower ARSA level was correlated with 
cognitive dysfunction in our previous study12, the PD duration-specific pattern of ARSA activity in the current 
study indicated that deficiency in ARSA activity may lead to detrimental effects on nigrostriatal dopaminergic 
neurons. Thus, elevation of ARSA activity in relation to nigrostriatal degeneration in the early stage of PD might 
be a compensatory phenomenon in response to intracellular accumulation of aggregated α-synuclein. This result 
would provide a new perspective on the role of lysosomal enzyme in the early stage of PD and its importance as 
a fluid biomarker of disease progression.
Although the exact source and tissue contribution of plasma ARSA have not been fully elucidated, ARSA is 
broadly expressed in brain residing cells and in lymphocytic cells in the blood, spinal cord, and peripheral tissues, 
and is also secreted from cells16. In addition, a previous study has reported that some exosomes present in the sera 
contain lysosomal enzymes17. In Alzheimer’s disease, the levels of plasma lysosomal enzymes vary depending on 
disease progression and are more sensitive to cellular metabolic alteration compared to the levels of amyloid-β 
peptide or tau proteins18. Moreover, when considering the peripheral-onset hypothesis of the formation of abnor-
mal α-synuclein aggregates19, alteration in the activity of lysosomal enzyme in peripheral blood may already 
reflect the general lysosomal dysfunction in PD. As in the case of other lysosomal enzymes, our data provide 
further evidence showing that plasma ARSA is correlated to PD progression. Future studies on whether the level 
of lysosomal enzyme in the peripheral blood is correlated to the activity of lysosomal enzyme in brain samples 
with PD or dopaminergic neurons are needed.
The present study has several limitations: First, this is a cross-sectional study and, therefore, provides limited 
grounds for a compensatory role of ARSA in individual level, longitudinally. Serial measures of the plasma ARSA 
level are required to elucidate actual changes in the plasma ARSA as PD progresses. Second, this study was based 
on a relatively small sample, especially the control and late PD groups, which limits the generalizability of our 
study. Third, we quantified the plasma ARSA level using Western blot. Since we were unable to measure ARSA 
level in human plasma samples using ARSA activity assay, it is necessary to develop a more accurate method for 
measuring ARSA levels in plasma and demonstrate its validity and reliability as a compensatory biomarker for 
early PD.
In summary, the plasma ARSA level was elevated in the early stage of PD in relation to nigrostriatal degener-
ation and was reduced in the late stage, showing an inverted U-shape according to disease duration. These results 
indicated that the peripheral metabolism of lysosomal enzymes could be a potential biomarker of compensation 
in early PD.
Materials and Methods
participants. We consecutively recruited HC and patients with PD between June 2015 and November 2017 
at the movement disorders outpatient clinic in Yonsei University Health System. The participants in the control 
group did not have any subjective symptoms of cognitive impairment or a history of neurologic or psychiatric 
illnesses. All participants in the control group had normal cognitive function according to Korean version of 
Figure 2. (A) Correlation between plasma ARSA level and the UPDRS motor score. (B) Correlation between 
plasma ARSA level and the striatal dopamine transporter activity. In all analyses, age, sex, and total K-MMSE 
score were used as covariates. ARSA, arylsulfatase A; AU, arbitrary unit; DAT, dopamine transporter; K-MMSE, 
Korean version of the Mini-Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s 
Disease Rating Scale.
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the Mini-Mental State Examination (K-MMSE scores ≥ 26). We have recruited two groups of patients with PD: 
one group had less than 5 years of disease duration with drug-naïve state (early PD group, n = 55) and the other 
group had more than 5 years of disease duration and were taking dopamine medications (late PD group, n = 13). 
Diagnosis of PD was based on the clinical diagnostic criteria of the United Kingdom PD Society Brain Bank20, 
and only patients diagnosed with PD who responded to dopaminergic medication during the follow-up period 
(≥ 6 months) were included in this study. The early PD group in this study had undergone N-(3-[18F]fluoro-
propyl)−2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) positron emission tomography (PET) 
imaging at the time of their PD diagnosis, which revealed decreased uptake. The exclusion criteria included 
any evidence of motor, autonomic, oculomotor, and cognitive or neurobehavioral features indicative of atypical 
parkinsonism21; focal brain lesions, severe white matter hyperintensities22, multiple lacunes in the basal gan-
glia, or hydrocephalus on magnetic resonance imaging; or other neurologic, psychiatric, or metabolic illnesses. 
Parkinsonian motor symptoms were assessed during the drug-naïve state at the time of 18F-FP-CIT PET acqui-
sition using the Unified PD Rating Scale motor (UPDRS) part III subscales. The K-MMSE was used to assess 
general cognition.
This study was approved by the Institutional Review Board of Yonsei University Severance Hospital (4-2013-
0407). A written informed consent was obtained from all patients and healthy controls who participated in this 
study. All experiments were performed in accordance with the approved guidelines of the Institutional Ethical 
Committee.
Human plasma preparation. In total, 10 mL of plasma samples were drawn via venous puncture and were 
placed into EDTA tubes. Immediately after filling each tube, it was gently inverted 10 times. The blood tubes were 
allowed to stand at room temperature for approximately 30 min prior to centrifugation, which was performed for 
20 mins at 2000 rpm at 4 °C. The supernatant was aliquoted into 500 cc in 1.5 mL cryogenic vials. The aliquot of 
plasma was frozen in a freezer with a temperature of −75 °C or −80 °C until use.
Western blot analysis of plasma ARSA levels. We measured the plasma ARSA level of the study par-
ticipants using Western blot analysis (cropped images in Fig. 3; uncropped images in Supplementary Figure S1). 
To analyze ARSA protein levels, plasma preparations were mixed with SDS sample buffer and heated at 95 °C 
for 5 min. The samples were dissolved by 12% SDS-PAGE gel and then transferred onto a nitrocellulose mem-
brane. After incubation with PBS containing 0.1% Tween-20 and 5% skim milk for 30 min, the membrane was 
probed with anti-ARSA antibody (1:1,000; Abcam, ab174844, Cambridge, MA), followed by HRP-conjugated 
goat anti-rabbit IgG (1:5,000; Jackson Immunoresearch Laboratories, West Grove, PA). The chemiluminescence 
detection was performed using the Amersham Imager 600 (Ge Healthcare Life Sciences, Marlborough, MA) and 
the band intensity was quantified using the NIH ImageJ software.
pet-ct image acquisition. All participants were injected with 185 MBq (5 mCi) of 18F-FP-CIT and the 
PET images were obtained 90 min after injection. 18F-FP-CIT PET-CT acquisition was performed with a GE 
Discovery 600 PET/CT scanner (General Electric Healthcare, Milwaukee, MI, USA). The images were acquired 
for 15 min after CT scan for attenuation correction. The spiral CT scan was performed with the following param-
eters: 0.8 s/rotation at 120 kVp, 10 mA, 3.75-mm slice thickness, 0.625-mm collimation and 9.375-mm table feed 
per rotation. 18F-FP-CIT PET images were reconstructed using the ordered subset expectation maximization 
(OSEM) algorithm with four iterations and 32 subsets. Gaussian filter with 4-mm full-width at half-maximum 
(FWHM) was applied into the reconstructed PET images, which is a 256 × 256 matrix with 0.98-mm pixel and 
0.98-mm slice thickness.
Quantitation of the 18F-FP-CIT PET-CT images. Image processing was performed using the MATLAB 
(The MathWorks, Inc, Natick, MA) based software statistical parametric mapping (SPM8) and ITK-SNAP (http://
Figure 3. Western blot images (cropped) of plasma ARSA levels. Western blot analysis of plasma ARSA levels 
was performed in healthy controls (N = 14), early Parkinson’s disease (PD) group (N = 55), and late PD group 
(N = 13).
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www.itksnap.org). All reconstructed 18F-FP-CIT images were normalized to the 18F-FP-CIT template, which was 
made using the 18F-FP-CIT PET images and T1-weighted MRI images of the 40 healthy controls as described 
previously23. All healthy controls had no previous history of neurologic or psychiatric illness. They showed nor-
mal cognitive function based on all neuropsychological tests, and their neurologic examination, structural MRI, 
and 18F-FP-CIT PET findings were normal. For non-specific binding, the mean standardized uptake value was 
calculated by drawing two occipital volume-of-interests (VOI), one in each side. The level of DAT activity in 
striatal VOI was calculated in terms of the specific to non-specific binding ratio as follows: (mean standardized 
uptake of the striatal VOI – mean standardized uptake of the occipital VOI)/(mean standardized uptake of the 
occipital VOI).
Statistical analyses. The baseline demographic and clinical characteristics of the patients with PD and 
normal controls were analyzed. We used the Mann–Whitney U test or Kruskal–Wallis test for continuous varia-
bles and Pearson’s χ2 test for categorical variables. Analysis of covariance was used to compare the plasma ARSA 
level among the groups. Post-hoc subgroup comparisons were performed using the Bonferroni method. The 
generalized additive model was used to investigate the non-linear relationship between the plasma ARSA level 
and disease duration in all patients with PD. Partial correlation analysis was performed to evaluate the association 
between the plasma ARSA level and UPDRS motor score or striatal DAT activity in patients with early PD. We 
adjusted for age, sex, and total K-MMSE score as covariates in all statistical analyses except for the comparison of 
baseline demographic and clinical characteristics. Data were analyzed using R v3.5.2 (Institute for Statistics and 
Mathematics, Vienna, Austria; www.r-project.org). P-values < 0.05 were considered significant.
Data availability
Data generated in the present study are available from the corresponding author upon reasonable request.
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